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ABSTRACT 
A large amount of hidden biological information is contained in the human genome,  
which is not expressed or revealed in the form of proteins; the usual end product form of gene  
expression. Instead, most of such information is in the form of non-coding RNAs (ncRNAs).  
ncRNAs correspond to genes that are transcribed, but do not get translated into proteins. This  
part of the genome was, till recently, considered as ‘junk’. The term ‘junk’ implied lack of any  
discernible function of these RNA. More than 98% of the human genomic size encompasses  
these  non-coding RNAs.  But,  recent  research has  evidently  brought  out  the  indispensible  
contribution of non-coding RNA in controlling and regulating gene expression. ncRNA such as  
siRNAs and microRNAs have been reported to greatly help in  causing post-transcriptional  
gene silencing (PTGS) in cells through RNA interference (RNAi) pathway. In this work, we 
have investigated the possibility of using siRNAs and microRNAs to aid in gene silencing of  
early onset Alzheimer’s disease genes. 
Alzheimer’s disease specific  mutations  and their  corresponding positions in  mRNA 
have been identified for six genes; Presenilin-1, Presenilin-2, APP (amyloid beta precursor  
protein), APBB3, BACE-1 and PSENEN. 
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Small  interfering  RNAs (siRNAs)  that  can  cause  PTGS through RNA interference  
pathway  have  been  designed.  RNA analysis  has  been  done  to  verify  complementarity  of  
antisense siRNA sequence with target mRNA sequence. Interaction studies have been done  
computationally between these antisense siRNA strands and seven Argonaute proteins. From 
the interaction studies, only one of the seven Argonaute proteins; 1Q8K, was found to have  
interaction with the siRNAs indicating the importance and uniqueness of this particular protein  
in RISC (RNA induced silencing complex).  
The interaction studies have been carried out for the microRNAs also. Out of the 700 
mature human microRNAs collected,  394 microRNAs have been identified to show partial  
complementarity with their target sequence on PSEN-1 mRNA.  Of these 394, five microRNAs  
have shown partial complementarity to early onset Alzheimer’s disease specific mutations in  
PSEN-1 mRNA. Interaction studies have been done between these microRNAs and Argonaute  
proteins.  Thus,  design,  characterization  and  analysis  of  ncRNAs  that  contribute  to  post  
transcriptional gene silencing of Alzheimer’s disease have been achieved.
INTRODUCTION    
An estimation of ‘United Nation population projection’ reminds that the number of 
people older than 80 years will become approximately 370 million by the year 2050. Current 
estimation is  that  about  half  the strength of  people older  than 85 years  are  affected with 
dementia. This statistics warns that within 50 years, above 100 million people will suffer from 
dementia.
The most common cause of dementia is Alzheimer's disease (AD). Alzheimer's disease 
is  caused  by  the  deposition  of  amyloid  plaques.   Amyloid  plaques  are  produced  by  the 
conversion of amyloid precursor protein (APP) into - amyloid (A ) .   Mutations in genes 
encoding amyloid precursor  protein (APP), presenilin-1 (position in chromosome 14),  and 
presenilin-2 (position in chromosome 1), APBB3, BACE1 and PSENEN causes Alzheimer’s 
disease. Thus mutated protein formed ultimately leads to Alzheimer’s disease. 
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Expression of mutated genes can be prevented by gene silencing techniques.  Gene 
silencing is done at the transcriptional and post transcriptional levels. Post transcriptional gene 
silencing results in the destruction or inactivation of the mRNA of the intended gene. This 
prevents the mRNA from producing an active gene product; a protein. The most common 
mechanism of post transcriptional gene silencing (PTGS) is the RNA interference (RNAi), 
wherein the mRNA inactivation is done by means of non-coding RNAs (ncRNAs). The term 
non-coding RNA (ncRNA) means RNA that does not encode a protein. Such RNAs can have 
specific biological functions. For example, tRNA which is non-coding has specific function in 
transport of amino acids during translation. Noncoding RNA has a role in heterochromatic 
silencing,  silencing  of  transposable  elements  (TEs),  unpaired  DNA  in  meiosis,  and 
developmentally excised DNA [3]. Most of the functions of ncRNAs are unknown. Non-coding 
RNAs are formed at a higher rate than messenger RNAs [4]. Some of the different ncRNAs are 
small interfering RNAs (siRNAs), microRNAs (miRNAs), piwi interacting RNAs (piRNAs), 
transfer RNAs (tRNAs), ribosomal RNAs (rRNAs) and so on.
Double stranded non-coding RNAs (dsRNA; >200 nucleotides length) can initiate RNA 
interference pathway, once injected into the cell. Initially, the dsRNA is cleaved into smaller 
segments by an RNase enzyme called Dicer. These small segments (20-25 nucleotides length) 
are called small interfering RNAs (siRNAs). Each double stranded siRNA has a sense strand 
and an antisense strand. The sense strand is identical to a portion of the target mRNA sequence 
and the antisense strand is complementary to this sequence. The antisense strand then binds to 
the  Argonaute  protein  present  in  the  RNA induced silencing complex (RISC) of  the  cell 
cytoplasm. The RISC is a multiprotein endonuclease complex that catalyzes the destruction of 
the target mRNA, in the RNA interference pathway. 
The Argonaute protein has been identified to have a major role in RNA interference 
pathway. When double stranded siRNA is introduced into the cell, one strand of siRNA; the 
antisense strand binds with Argonaute protein. When binding of the antisense strand occurs the 
sense strand gets unwound from the siRNA duplex and gets dissolved. Even though sense 
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strand is a part of mRNA, mRNA does not get dissolved because its dimensionality is very 
high compared to sense strand.  If  an mRNA complementary to Argonaute bound RNA is 
detected, then it can bind to the mRNA complementarily through base pairing between target 
mRNA sequence and Argonaute bound antisense siRNA. This binding would thereby cleave 
the mRNA at its central position and eventually degrade it. Thus the gene corresponding to that 
code is silenced at the mRNA level and protein encoding by that mRNA cannot be further done 
[1].  siRNA can be created in  test  tube conditions or  can be synthesized from the double 
stranded RNA viruses. Computationally, siRNA can be designed in such a way that its sense 
strand  is  identical  to  the  target  sequence  present  inside  mRNA  and  antisense  strand 
complementary to this target sequence.
 MicroRNAs of length 21-22 nucleotides are found in eukaryotes that can act through 
RNA interference (RNAi).  A complex of miRNA and enzymes can break down the target 
mRNA. Here, the miRNA is complementary to the target mRNA and blocks the mRNA from 
being translated or accelerates its degradation [6]. 
Small interfering RNA (siRNA) and microRNA (miRNA) are anchored into specific binding 
pockets of Argonaute protein and guide it to target mRNA molecules to prevent decoding of 
protein information during translation. Argonaute proteins are evolutionarily conserved. They 
can be phylogenetically subdivided as Ago subfamily and the Piwi subfamily. Ago proteins are 
ubiquitously expressed. They can bind to siRNAs or miRNAs to guide post-transcriptional 
gene silencing. Piwi proteins are mostly expressed in the germ line and these proteins can 
associate with piRNAs to facilitate silencing of mobile genetic elements [7]. Thus, Argonaute 
proteins can interact or bind to small non-coding RNAs with its functional domains and control 
protein synthesis by affecting messenger RNA stability and they can also participate in the 
production of a new class of small RNAs called Piwi-interacting RNAs [8]. 
Several  domains  of  Argonaute  proteins  have  already  been  identified  in  RNA 
interference.  The PAZ domain constitutes 110 amino-acids and is  named so because it  is 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
10
.4
46
7.
1 
: P
os
te
d 
18
 M
ay
 2
01
0
contained in Piwi, Argonaute and Zwille/Pinhead proteins [10]. The Tudor domain exhibits a 
conserved negatively charged surface which can interact with the C-terminal Arg and Gly-rich 
tails of proteins [11]. Thermo nuclease domain can catalyze the hydrolysis of both DNA and 
RNA at 5' position of the phosphodiester bond and give 3'-mononucleotides and dinucleotides. 
Two arginines and one glutamate are implicated in the catalytic mechanism. [12].  
MATERIALS AND METHODS
Mutation records on genes that lead to Alzheimer’s disease have been collected from 
‘Human Genome Mutation Database’ (HGMD) [13]. mRNA sequences of these AD causing 
genes have been collected from NCBI database [14].
Mutations  have  been  identified  in  genes  that  code  for  presenilin-1,  presenilin-2, 
amyloid precursor protein (APP), BACE-1 and PSENEN proteins. These mutations in genes 
are  copied  into  open  reading  frame  (ORF)  of  mRNA  during  transcription.  Thus,  the 
corresponding mutations in ORF of mRNA have been identified. The target regions on mRNA 
into which siRNAs can bind have been identified using siRNA target finder tool [15]. Sense 
strands of siRNA of length 20-25 nucleotides have been designed that are identical to the 
mutated regions of mRNA. Antisense strands of siRNA have been designed by considering 
complementarity with the sense strands. Thus the designed complementary antisense siRNA 
strand is also complementary to the mutated region of target mRNA. Hyperchem tool has been 
used to build all antisense siRNAs insilco [17].
Guanine  and  cytosine  content  (GC  content)  of  all  antisense  siRNAs  have  been 
identified. If GC content of one strand of siRNA is greater than 60% it  cannot become a 
functional siRNA because bond between guanine and cytosine is a triple bond. These bonds are 
much stronger compared to A-U or A-T double bonds and each strand of  siRNA can have a 
tendency to form loops by itself . This may prevent the strands from binding to their target 
mRNA.  Therefore GC percentage has been checked for each siRNA strand.
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RNA analysis of the antisense siRNA strands has been done using RNAfold tool to 
identify self-complementarity among nucleotides, secondary structure formation tendency with 
respect to base pair distance within the sequence and thermodynamic energy differences among 
different  antisense siRNA sequences.  Complementarity  of  bases  between antisense siRNA 
strand and the target mRNA sequence and thermodynamic energy of antisense siRNA strand 
bound to target mRNA sequence were found using RNAcofold tool [16].
Seven Argonaute proteins; 1Q8K, 1S12, 1S13, 2E6N, 2HQE, 2HQX and 3BDL, in 
human were collected from Protein Data Bank (PDB) database [18]. These proteins have been 
subjected to primary and secondary structure analyses. Secondary structure, class and species 
details of proteins were collected from SCOP database [20].  Percentage of alpha helix and beta 
turns were identified for each proteins using SOPMA tool [21]. Prosite tool was used to find 
domains in proteins [22]. A domain is a region in the protein, where an active site or motif can 
be found out.  ProtParam tool was used to find molecular weight, theoretical PI, hydrophilicity 
and stability of proteins [23]. If GRAVY (Grand Average Hydropathicity) is positive, then 
protein is hydrophobic and if negative, protein is hydrophilic. Antisense siRNAs were docked 
with  the  seven  Argonaute  proteins  present  in  human using  CDOCKER tool  of  Accelrys 
Discovery studio [24].
Mature human microRNAs were collected from miRBase database to analyze whether 
they can bind to Alzheimer’s disease specific mutated regions on target mRNA [25]. Out of 
700  mature  human  microRNAs,  394  microRNAs  have  been  identified  using 
microINSPECTOR tool which showed partial complementarity with their target sequence on 
PSEN-1  mRNA  [26].   Of  these  394  microRNAs,  five  microRNAs  have  shown  partial 
complementarity to early onset Alzheimer’s disease specific mutations in PSEN-1 mRNA. 
Interaction studies have been done between these microRNAs and Argonaute proteins.
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RESULTS AND DISCUSSIONS
Antisense strands of siRNA of length 20 nucleotides have been designed complementary to 
nine early onset Alzheimer’s disease specific mutated regions in mRNA encoded by PSEN-1 
gene. Two siRNAs show high GC content in its antisense strand (above 60%). siRNA with GC 
content greater than 60% are non-functional. So, it cannot be consider in post transcriptional 
gene silencing. 46 functional siRNAs are designed against 72 Alzheimer’s disease specific 
mutated  regions  in  mRNA  encoded  by  PSEN-1  gene.  53  functional  siRNAs  have  been 
designed for 81 mutated regions in mRNA encoded by PSEN-1 gene.  Details of siRNAs 
designed against mutated regions on mRNA of PSEN-2, APP, APBB3, BACE-1 and PSENEN 
genes are given in Table 7.1. The sequences that have high base-pair complementarity among 
themselves are not  feasible to be considered in post transcriptional gene silencing because if 
these strands form rigid secondary structures by themselves, then their binding sites to the 
target mRNA may decrease.   Fig.7.1  represents thermodynamic free energy of antisense 
strands  designed  complimentary  to  mutated  region  of  PSEN-1  mRNA. X-axis  represents 
thermodynamic free energy of each antisense strand complimentary to the target sequence in 
the mRNA and Y-axis represents codon position numbers where mutation occurred in the 
mRNA.  Antisense strands with relatively strong internal structures are not feasible in post 
transcriptional gene silencing because they may make antisense strands incapable of binding to 
their target mRNA sequences. Thermodynamic free energy of antisense siRNA strand bound to 
target mRNA sequence has been identified as thermodynamically supportive.  
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Table-1 Details of siRNAs designed against mutated regions on mRNA of PSEN-2, APP, APBB3, BACE-1 
and PSENEN genes
Gene 
names 
encoding 
mutated 
mRNA
Number 
of 
functional 
siRNAs 
designed
Average 
GC
percentage
Complementarity 
of anti-sense 
strand of siRNA 
towards target 
mRNA
Codon position 
numbers on ORF of 
target mRNA in which 
their complimentary 
antisense strands 
shown interaction with 
Argonaute protein
Presenilin
-1
53 40% full 35,116,123,143, 214, 206, 
245, 386, 377, 378, 431, 
435, 436, 213, 267, 268, 
269, 278, 213, 219, 365, 
280, 139, 120, 209,115, 
409, 282, 284, 394, 384, 
318, 139, 222, 113
Presenilin
-2
3 52.35% full 122
APP 10 38.1% full 692,693,665,677,678,713,
714,715,716,717
APBB3 1 46.67% full 318
BACE1 2 45.72% full 118,452
PSENEN 1 42.9% full 90
Interaction studies have been done computationally between these antisense strands and 
Argonaute proteins. Interaction of these antisense strands has been           reported with only 
one out of the seven Argonaute proteins i.e. 1Q8K. It can be suggested that, antisense siRNA 
strands  that  do  not  show  interaction  with  the  antisense  strands  are  not  feasible  in  post 
transcriptional gene silencing because only those antisense siRNA strands that form a complex 
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with Argonaute can bind to the target mRNA.  This binding cleaves the target mRNA or 
prevents it from being used as a translation template. The result of computation of interaction 
energy  between  antisense  siRNA strands,  complementary  to  mutated  regions  on  PSEN-1 
mRNA, and conformers of Argonaute protein 1Q8K has been included in Fig.7.1.  
Fig. 7.1 Interaction energy between antisense siRNA strands (complementary to mutated regions on 
PSEN-1 mRNA) and 1Q8K protein conformers
Similarly, the results of computation of interaction energy between conformers of argonaute 
protein 1Q8K  and antisense  siRNA strands, complementary to mutated regions on PSEN-2 
mRNA, APP mRNA and  BACE-1 mRNA  have been included in Fig.7.2, Fig.7.3 and Fig.7.4. 
All these  interactions are exothermic and thermodynamically supportive. 
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Fig.7.2 Interaction energy between antisense siRNA strands, (complementary to mutated regions on 
PSEN-2 mRNA) and 1Q8K protein conformers
Fig.7.3 Interaction energy between antisense siRNA strands complementary to mutated regions on APP 
mRNA and Argonaute proteins.
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Fig. 7.4 Interaction energy between antisense siRNA strands complementary to mutated regions on 
BACE-1 mRNA and Argonaute proteins.
One antisense siRNA strand has been designed complimentary to mutated region of 
APBB3 mRNA and one designed for  PSENEN mRNA. These two antisense siRNA have 
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shown interaction with 1Q8K protein. Table-2 shows interaction energy of antisense siRNA 
strands complimentary to mutated region of APBB3 mRNA and PSENEN mRNA. 
Table-2 interaction energy of antisense siRNA strands complimentary to mutated region of 
APBB3 mRNA and PSENEN mRNA
Gene names 
encoding 
mutated 
mRNA
Protein 
conformer id
Codon position number 
in ORF of mRNA that is 
complementary to the 
designed antisense 
siRNA strand
Interaction 
energy(kcal/mol)
APBB3 1Q8K_mod4 318 -167.82
PSENEN 1Q8K_mod9 90 -187.89
Mature human microRNAs that are partially complementary to mutated regions of early 
onset  Alzheimer’s  disease  specific  mutations  in  PSEN-1  mRNA  are  shown  in  Table-3. 
Complementarity  is  shown  in  table  as  dot-bracket  notation.  Dot  symbol  represents  one 
nucleotide  in  the  sequence.  Each  opening  and  closing  bracket  represents  one  base  pair. 
MicroRNA and target sequence is separated by ampersand symbol (&). 
Table-3 Details of mature human microRNAs that are partially complementary to mutated regions of 
early onset Alzheimer’s disease specific mutations in PSEN-1 mRNA
Name of 
mature 
human 
microRNA
codon 
change 
on target 
PSEN-1 
gene due 
to 
mutation
Complementarity of 
microRNA with target 
sequence that include 
mutation in PSEN-1 mRNA
Thermody
namic free 
energy of 
heterodim
er formed. 
(Kcal/mol)
Argonaute 
protein 
name
Interaction 
energy of 
microRNA 
with 
Argonaute 
protein 
(Kcal/mol)
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hsa-mir-214 ATT-
AAT
Complementary microRNA:
ACAGCAGGCACAGACAG
GCAGU
Target mRNA sequence with 
mutation position:-
AAUGCUGCCAUCAUGAU
CAGUGUCAAUGUUGU
(((((((((((.((((((((((&...))))))....)
).)).)))))..))))))
-21.24 1Q8K_mod
4
-168.348
hsa-miR-371 TTT-
ATT
Complementary microRNA:
AAGUGCCGCCAUCUUUU
GAGUGU
Target mRNA sequence with 
mutation position:-
AGUCAGCAUUAUACCCG
GAAGGAUGGGCAGCU
....((.(((.(((((((.((((&..........)))).)
))))))...))).)).
-17.80
No 
interaction Nil
hsa-mir-450b-
3p
GGT-
GAT
Complementary microRNA:-
UUGGGAUCAUUUUGCAU
CCAUA
Target mRNA sequence with 
mutation position:-
UGGAAUUUUGAUGUGGU
GGGAAUGAUUUCCAU
.((((((((((((.(((((((.&..........))).))
))))))))).))))).
-17.91 No 
interaction
Nil
hsa-mir-936 CAC-
TAC
Complementary microRNA:
ACAGUAGAGGGAGGAAU
CGCAG
Target mRNA sequence with 
mutation position:-
UUGAUGUGGUGGGAAUG
AUUUCCAUUUACUGG
.((((((((((((..((((((.&....))))))......
..))))).))))))).
-18.25 1Q8K_mod
4
-144.331
hsa-mir-202 CTT-
CAT
Complementary microRNA:-
AGAGGUAUAGGGCAUGG
GAA
Target mRNA sequence with 
mutation position:-
GUCAUCCAUGCCUGGCA
UAUUAUAUCAUCUCU
((((((((((((((((((..&....)))))))))....
...)))))).))).
-20.37 No 
interaction
Nil
CONCLUSION
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Antisense siRNA strands that show comparatively stronger interaction with argonaute 
protein may be able to form RNA-protein complex. This complex can recognize target mRNA 
sequence by considering base pair complementarity and can bind through hydrogen bonds. 
Antisense siRNA strands designed with comparatively low GC content, and their interaction 
with protein argonaute indicates feasibility of designed siRNA strands to be used in RNA 
interference pathway to            silence AD specific mutations. Antisense siRNA strands have 
shown  more  complementarity  with  their  target  mRNA  sequence  than  mature  human 
microRNAs. These strands are more thermodynamically stable than human microRNAs when 
bound with their target mRNA sequence. This implies that siRNA strands that are designed are 
more efficient to be used in post transcriptional gene silencing than human microRNAs.  
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